ProMetic Life Sciences Inc. (TSE:PLI) insider Jonathan Booth acquired 75,000 shares of the business’s stock in a transaction on Friday, October 6th. The shares were bought at an average price of C$1.21 per share, with a total value of C$90,750.00.
COPYRIGHT VIOLATION WARNING: This article was posted by Stock Observer and is owned by of Stock Observer. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.thestockobserver.com/2017/10/13/jonathan-booth-acquires-75000-shares-of-prometic-life-sciences-inc-pli-stock.html.
PLI has been the subject of several research reports. National Bank Financial raised their price objective on shares of ProMetic Life Sciences from C$2.00 to C$2.50 in a research report on Wednesday, August 30th. Scotiabank cut their price objective on shares of ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating for the company in a research report on Friday, July 7th. Canaccord Genuity cut their price objective on shares of ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating for the company in a research report on Monday, June 19th. TD Securities cut their price objective on shares of ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a research report on Wednesday, August 16th. Finally, Royal Bank Of Canada lowered their target price on shares of ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating on the stock in a report on Wednesday, August 16th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of C$3.60.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.